8/9/2022 7:27:12 AM
Epizyme Q2 Net Loss Attributable To Common Stockholders $35.7
mln Or $0.21/Shr Vs $64.4 Mln Or $0.63/Shr Last Year
6/27/2022 1:04:48 AM
Ipsen To Buy Epizyme; Deal Anticipated To Close By End Of Q3
5/10/2022 7:12:02 AM
Epizyme Q1 Total Revenue $8.7 Mln, Increase Of 14% From Prior Year
4/6/2022 7:03:02 AM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/15/2022 7:05:36 AM
Epizyme Appoints Jerald Korn As COO
3/1/2022 7:10:11 AM
Epizyme Q4 Loss/shr $0.49 Vs. Loss/shr $0.65 Last Year
1/27/2022 2:24:41 AM
Epizyme Announces Pricing Of Underwritten Public Offering Of 56.67 Mln Shares At $1.50/shr
12/12/2021 9:06:15 AM
Epizyme Presents Updates From SYMPHONY-1 Tazemetostat + R2 Study In Relapsed/Refractory Follicular Lymphoma At ASH
11/9/2021 6:36:44 AM
Epizyme Q3 Net Loss $65.8 Mln Or $0.64/shr Vs. Net Loss $56.1 Mln Or $0.55/shr Last Year
11/4/2021 6:39:02 AM
Epizyme Gets Fast Track Designation From FDA; Initiates Phase 1/1b Study Of SETD2 Inhibitor, EZM0414
10/7/2021 7:07:45 AM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/14/2021 6:34:57 AM
Epizyme Presents Data From TAZVERIK Clinical Programs At 2021 ESMO Congress
8/20/2021 8:06:18 AM
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/9/2021 7:38:39 AM
Epizyme Says Grant Bogle Succeeding Robert Bazemore, As President And CEO
8/9/2021 7:36:46 AM
Epizyme Q2 Total Revenue Rises To $13.0 Mln From $2.5 Mln Last Year